ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Hidetoshi Tsuboi
Kensuke Esato
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mori, F.
Right arrow Articles by Esato, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mori, F.
Right arrow Articles by Esato, K.

Ann Thorac Surg 1990;49:413-418
© 1990 The Society of Thoracic Surgeons

Articles

Clinical trial of nicardipine cardioplegia in pediatric cardiac surgery

Fumiki Mori, MD*, Masaki Miyamoto, MD, Hidetoshi Tsuboi, MD, Hiroshi Noda, MD, Kensuke Esato, MD

First Department of Surgery, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan

Accepted for publication September 27, 1989.

* Address reprint requests to Dr Mori, First Department of Surgery, Yamaguchi University School of Medicine, Ube, Yamaguchi 755, Japan.

To clarify the effectiveness of nicardipine, one of the dihydropyridine calcium channel blockers, for myocardial protection during cold potassium cardioplegic arrest in pediatric cardiac surgery, a clinical trial of nicardipine (0.25 mg/L) added to potassium cardioplegic solution was performed in children undergoing surgical repair of congenital heart diseases. Twenty patients were selected to receive nicardipine cardioplegia and 13 patients received a standard potassium cardioplegia, serving as a control group. Nicardipine cardioplegia provided better cardiac performance in the early postoperative period and reduced release of the MB isozyme of creatine kinase, as determined during a 48-hour postoperative period. These results suggest that nicardipine added to cold potassium cardioplegic solution offers additional protection for the myocardium during ischemia and postischemic reperfusion in pediatric cardiac surgery.




This article has been cited by other articles:


Home page
 Eur J Cardiothorac SurgHome page
M. Ruel, T. A. Khan, P. Voisine, C. Bianchi, and F. W. Sellke
Vasomotor dysfunction after cardiac surgery
Eur J Cardiothorac Surg, November 1, 2004; 26(5): 1002 - 1014.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
P. J. del Nido
Myocardial Protection and Cardiopulmonary Bypass in Neonates and Infants
Ann. Thorac. Surg., September 1, 1997; 64(3): 878 - 879.
[Full Text]

Home page
 Ann. Thorac. Surg.Home page
E. R. Rosenkranz
Substrate enhancement of cardioplegic solution: Experimental studies and clinical evaluation
Ann. Thorac. Surg., September 1, 1995; 60(3): 797 - 800.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
P. S. Brown, G. L. Parenteau, F. W. Holland, and R. E. Clark
Pretreatment with nicardipine preserves ventricular function after hypothermic ischemic arrest
Ann. Thorac. Surg., May 1, 1991; 51(5): 739 - 746.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1990 by The Society of Thoracic Surgeons.